Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies.

JNCI Cancer Spectr · 2026 · PMC13354522 · PMID 42185079

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

After adjusting for chemotherapy, relapse-free survival was longer in carriers than noncarriers in COQD (adjusted hazard ratio = 0.48 [95% CI = 0.26 to 0.87], P = .016), and a favorable trend was observed for other survival outcomes in both cohorts.

also in 993 other papers

a numerical trendno p-value reported

In the YWS cohort, survival outcomes were comparable for young women with or without gBRCA PV, although a numerical trend toward better long-term outcomes was observed for gBRCA PV carriers vs noncarriers (3-year RFS = 85.5% vs 83.3%, 8-year RFS = 81.2% vs 72.1%).

also in 723 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.